Hmdb loader
Survey
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2007-04-12 20:18:38 UTC
Update Date2021-09-14 15:40:10 UTC
HMDB IDHMDB0006012
Secondary Accession Numbers
  • HMDB06012
Metabolite Identification
Common NameEpimetendiol
DescriptionEpimetendiol is one of the major urinary metabolites of the anabolic androgenic compound metandienone. Anabolic-androgenic steroids such as metandienone are some of the most frequently detected drugs in amateur and professional sports. Doping control laboratories have developed numerous assays enabling the determination of administered drugs and/or their metabolic products that allow retrospectives with respect to pharmacokinetics and excretion profiles of steroids and their metabolites. Metandienone misuse can be detected by high resolution mass spectrometry for a prolonged period after stopping the intake of metandienone. Androgenic anabolic steroids are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. The use of anabolic steroids was banned by the International Olympic Committee for the first time at the Olympic Games in Montreal in 1976. Androgenic anabolic steroids (AAS) are defined as natural, synthetic or semi-synthetic drugs chemicals derived from testosterone, used with the aim to improve physical performance by increasing both muscle strength and mass. Despite their reported toxicological effects on the cardiovascular, hepatic and neuro-endocrine systems, the AAS have been extensively used in sports activities. (PMID: 16804957 , 10595716 , 10506840 , 1089834 , 14085300 , 14141174 , 3279830 , 4231505 , 4361633 , 4592844 , 4612989 , 4896687 , 4907221 , 4942579 , 6394898 ).
Structure
Data?1582752371
Synonyms
ValueSource
(3a,5b,17a)-17-Methyl-androst-1-ene-3,17-diolHMDB
17-EpimetendiolHMDB
17b-Methyl-5b-androst-1-ene-3a,17a-diolHMDB
Chemical FormulaC21H34O2
Average Molecular Weight318.4935
Monoisotopic Molecular Weight318.255880332
IUPAC Name(1S,2R,5S,7R,10R,11S,14R,15S)-2,7,14,15-tetramethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-ene-5,14-diol
Traditional Name(1S,2R,5S,7R,10R,11S,14R,15S)-2,7,14,15-tetramethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-ene-5,14-diol
CAS Registry Number132830-78-5
SMILES
[H][C@@]12CC[C@@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2(C)C[C@H](O)C=C[C@]12C
InChI Identifier
InChI=1S/C21H34O2/c1-18-9-6-15-16(19(18,2)10-5-14(22)13-18)7-11-20(3)17(15)8-12-21(20,4)23/h5,10,14-17,22-23H,6-9,11-13H2,1-4H3/t14-,15-,16+,17+,18-,19-,20+,21-/m1/s1
InChI KeyNZDUEHZAWOAARB-BWTDTTKRSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • Androgen-skeleton
  • 17-hydroxysteroid
  • 3-alpha-hydroxysteroid
  • Hydroxysteroid
  • 3-hydroxysteroid
  • 3-hydroxy-delta-1-steroid
  • Delta-1-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Process
Role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.003 g/LALOGPS
logP4.2ALOGPS
logP3.58ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)17.82ChemAxon
pKa (Strongest Basic)-0.49ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 ŲChemAxon
Rotatable Bond Count0ChemAxon
Refractivity94.71 m³·mol⁻¹ChemAxon
Polarizability38.03 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+175.48131661259
DarkChem[M-H]-171.63731661259
DeepCCS[M-2H]-207.72730932474
DeepCCS[M+Na]+182.01730932474
AllCCS[M+H]+182.532859911
AllCCS[M+H-H2O]+179.732859911
AllCCS[M+NH4]+185.132859911
AllCCS[M+Na]+185.932859911
AllCCS[M-H]-187.332859911
AllCCS[M+Na-2H]-187.832859911
AllCCS[M+HCOO]-188.432859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Epimetendiol[H][C@@]12CC[C@@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2(C)C[C@H](O)C=C[C@]12C2457.6Standard polar33892256
Epimetendiol[H][C@@]12CC[C@@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2(C)C[C@H](O)C=C[C@]12C2618.5Standard non polar33892256
Epimetendiol[H][C@@]12CC[C@@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2(C)C[C@H](O)C=C[C@]12C2619.0Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Epimetendiol,1TMS,isomer #1C[C@]12C=C[C@@H](O)C[C@@]1(C)CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(C)O[Si](C)(C)C2680.3Semi standard non polar33892256
Epimetendiol,1TMS,isomer #2C[C@]12CC[C@H]3[C@@H](CC[C@]4(C)C[C@H](O[Si](C)(C)C)C=C[C@]34C)[C@@H]1CC[C@@]2(C)O2656.8Semi standard non polar33892256
Epimetendiol,2TMS,isomer #1C[C@]12C=C[C@@H](O[Si](C)(C)C)C[C@@]1(C)CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(C)O[Si](C)(C)C2667.6Semi standard non polar33892256
Epimetendiol,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@]1(C)CC[C@H]2[C@@H]3CC[C@]4(C)C[C@H](O)C=C[C@]4(C)[C@H]3CC[C@@]21C2928.5Semi standard non polar33892256
Epimetendiol,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)O[C@@H]1C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(C)O)[C@@H]3CC[C@]2(C)C12933.2Semi standard non polar33892256
Epimetendiol,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)O[C@@H]1C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(C)O[Si](C)(C)C(C)(C)C)[C@@H]3CC[C@]2(C)C13199.0Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Epimetendiol GC-MS (Non-derivatized) - 70eV, Positivesplash10-0udi-0394000000-550212ab13569642c1f32017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Epimetendiol GC-MS (2 TMS) - 70eV, Positivesplash10-0002-3136900000-d40337e4da1bc1df9b8b2017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Epimetendiol GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Epimetendiol GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 10V, Positive-QTOFsplash10-0uxr-0029000000-fc9865121ee7b1a497662017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 20V, Positive-QTOFsplash10-0ue9-0396000000-23faa0a0e0e8a98a21d82017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 40V, Positive-QTOFsplash10-0fbc-2790000000-72b932c273db57d4e4f52017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 10V, Negative-QTOFsplash10-014i-0039000000-87ba1293bec3050192f52017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 20V, Negative-QTOFsplash10-014j-0079000000-ec3aee49be5fc73a2c1b2017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 40V, Negative-QTOFsplash10-0uki-0193000000-82cef7e42d20d19603ba2017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 10V, Positive-QTOFsplash10-0ue9-0069000000-ca491da3e19bbe899e4c2021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 20V, Positive-QTOFsplash10-0079-2921000000-f33041070d4a0d36b6052021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 40V, Positive-QTOFsplash10-004i-2900000000-729e8a52c9b9a279d0e12021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 10V, Negative-QTOFsplash10-014i-0009000000-bbaa566ea695ae62f84e2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 20V, Negative-QTOFsplash10-014i-0009000000-bbaa566ea695ae62f84e2021-09-24Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Epimetendiol 40V, Negative-QTOFsplash10-014i-0039000000-7eb484efeb5b1fc04f1b2021-09-24Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Extracellular
  • Membrane
Biospecimen LocationsNot Available
Tissue LocationsNot Available
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDFDB023801
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound53477798
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Kokkonen J, Leinonen A, Tuominen J, Seppala T: Comparison of sensitivity between gas chromatography-low-resolution mass spectrometry and gas chromatography-high-resolution mass spectrometry for determining metandienone metabolites in urine. J Chromatogr B Biomed Sci Appl. 1999 Nov 12;734(2):179-89. [PubMed:10595716 ]
  2. Schanzer W, Geyer H, Fussholler G, Halatcheva N, Kohler M, Parr MK, Guddat S, Thomas A, Thevis M: Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Commun Mass Spectrom. 2006;20(15):2252-8. [PubMed:16804957 ]
  3. Habscheid W, Abele U, Dahm HH: [Severe cholestasis with kidney failure from anabolic steroids in a body builder]. Dtsch Med Wochenschr. 1999 Sep 10;124(36):1029-32. [PubMed:10506840 ]
  4. Fedorov IV: [Biochemical changes in skeletal muscles during hypokinesia and possible means for counteracting them]. Kosm Biol Aviakosm Med. 1975 Jan-Feb;9(1):3-8. [PubMed:1089834 ]
  5. LARON Z, GITTER S: ANABOLIC STEROIDS: THEIR CLINICAL USE AND SPECIFIC DANGERS IN PEDIATRICS. Clin Pediatr (Phila). 1963 Nov;2:594-600. [PubMed:14085300 ]
  6. TAINTER ML, ARNOLD A, BEYLER AL, POTTS GO, ROTH CH: ANABOLIC STEROIDS IN THE MANAGEMENT OF THE DIABETIC PATIENT. N Y State J Med. 1964 Apr 15;64:1001-9. [PubMed:14141174 ]
  7. Pope HG Jr, Katz DL: Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988 Apr;145(4):487-90. [PubMed:3279830 ]
  8. Moldawer M: Anabolic agents: clinical efficacy versus side effects. J Am Med Womens Assoc. 1968 Apr;23(4):352-69. [PubMed:4231505 ]
  9. Herbst AL: Exogenous hormones in pregnancy. Clin Obstet Gynecol. 1973 Dec;16(4):37-50. [PubMed:4361633 ]
  10. Hirst AE Jr, Gore I: Marfan's syndrome: a review. Prog Cardiovasc Dis. 1973 Sep-Oct;16(2):187-98. [PubMed:4592844 ]
  11. Adigamov LF, Nesterin MF: [Metabolism of hormonal growth stimulants and chemical methods for determining them (a review of the literature)]. Vopr Pitan. 1973 Nov-Dec;(6):43-50. [PubMed:4612989 ]
  12. Zharov EI, Segal' RG: [Use of anabolic hormones for the treatment of cardiovascular patients]. Kardiologiia. 1969 Jan;9(1):144-53. [PubMed:4896687 ]
  13. Marks V, Salmols E: [Glucagon mediated insulin release in man]. Acta Diabetol Lat. 1968 Oct;5 Suppl 1:285-308. [PubMed:4907221 ]
  14. Mossor-Ostrowska J: [Anabolic steroids in the treatment of liver diseases]. Pol Tyg Lek. 1971 Aug 9;26(32):1248-51. [PubMed:4942579 ]
  15. Badalian LO, Temin PA, Mukhin KIu: [Treatment problems using anabolic steroids in progressive muscular dystrophy]. Klin Med (Mosk). 1984 Nov;62(11):23-9. [PubMed:6394898 ]